Kurma Biofund IV aims to invest in projects and companies in the Life science in Europe and outside Europe, meeting an important medical need. True to its core strategy, Kurma aims to make approximately twenty investments through Biofund IV, focusing on startups as well as the ex-nihilo ... Kurma Partners, a French healthcare VC firm, has closed their Biofund IV at €215 million to support the discovery and development of disruptive ...
This profile has not yet been verified by the firm. Information may be incomplete or outdated. Claim this profile to take control of your listing.
Location
France
Claim this profile to complete your information, set investment criteria, and start receiving curated deal flow from sponsors on DEALITHIC.